Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarlatamab (Primary)
Indications Adenocarcinoma; Brain metastases; Neuroendocrine carcinoma; Prostate cancer
Focus Adverse reactions
Acronyms DeLLpro-300
Sponsors Amgen

24 Oct 2024 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results(As of 28 March 2023, n=40 pts) reporting primary analysis data of tarlatamab in NEPC , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 May 2024 According to an Amgen media release, initial data from this study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in June.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com